ARCHIVES

In Brief: Columbia’s Marks Reportedly Will Move To MSK; FDA Committee to Consider THC For Group C List

This article is from The Cancer Letter archive.

Vol. 06 No. 21 | May 23, 1980

Download PDF Visit The Full Archive

Related Articles

Oblimersen Combination Improves CLL Survival

December 28, 2007

A Special Report: Language With A Purpose–von Eschenbach’s Four Years at NCI.

May 19, 2006

MSK Withdraws Form Breast Cancer Nutrition Study Over Chemotherapy Issue; Program Still “Going Well”

June 21, 1985

ASCO and CAP Issue Guideline To Improve HER2 Testing

October 25, 2013

NCI Programs: Coleman To Lead NCI’s New Radiation Oncology Program

February 5, 1999

Corrections Made To NCI Phone Directory

May 17, 1991